JP2008523056A - 蛍光造影剤 - Google Patents
蛍光造影剤 Download PDFInfo
- Publication number
- JP2008523056A JP2008523056A JP2007545401A JP2007545401A JP2008523056A JP 2008523056 A JP2008523056 A JP 2008523056A JP 2007545401 A JP2007545401 A JP 2007545401A JP 2007545401 A JP2007545401 A JP 2007545401A JP 2008523056 A JP2008523056 A JP 2008523056A
- Authority
- JP
- Japan
- Prior art keywords
- contrast agent
- group
- dihydrorhodamine
- optical imaging
- reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 96
- 230000004054 inflammatory process Effects 0.000 claims abstract description 34
- 239000007800 oxidant agent Substances 0.000 claims abstract description 31
- 206010061218 Inflammation Diseases 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 28
- 230000001590 oxidative effect Effects 0.000 claims abstract description 28
- 238000012634 optical imaging Methods 0.000 claims abstract description 26
- 239000007850 fluorescent dye Substances 0.000 claims description 92
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 claims description 33
- 230000008859 change Effects 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 239000000758 substrate Substances 0.000 claims description 19
- -1 cyclic polyols Chemical class 0.000 claims description 18
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 14
- 230000005284 excitation Effects 0.000 claims description 13
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 claims description 13
- 238000006911 enzymatic reaction Methods 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 102000035195 Peptidases Human genes 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 7
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 235000019833 protease Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 claims description 4
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 claims description 4
- 102000004366 Glucosidases Human genes 0.000 claims description 4
- 108010056771 Glucosidases Proteins 0.000 claims description 4
- 102000004316 Oxidoreductases Human genes 0.000 claims description 4
- 108090000854 Oxidoreductases Proteins 0.000 claims description 4
- BUJYUNAFKYHMAS-UHFFFAOYSA-N ethyl 2-[3,6-bis(ethylamino)-2,7-dimethyl-9h-xanthen-9-yl]benzoate Chemical compound C1=2C=C(C)C(NCC)=CC=2OC2=CC(NCC)=C(C)C=C2C1C1=CC=CC=C1C(=O)OCC BUJYUNAFKYHMAS-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000008163 sugars Chemical group 0.000 claims description 4
- 102000004157 Hydrolases Human genes 0.000 claims description 3
- 108090000604 Hydrolases Proteins 0.000 claims description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 3
- 101710088194 Dehydrogenase Proteins 0.000 claims description 2
- 108090000371 Esterases Proteins 0.000 claims description 2
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 102000005262 Sulfatase Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003172 aldehyde group Chemical group 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
- 150000007942 carboxylates Chemical group 0.000 claims description 2
- 238000002059 diagnostic imaging Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 108060007951 sulfatase Proteins 0.000 claims description 2
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000008033 biological extinction Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 235000019419 proteases Nutrition 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 230000003647 oxidation Effects 0.000 description 19
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 238000001228 spectrum Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 9
- 210000003714 granulocyte Anatomy 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- HACOCUMLBPNDIN-UHFFFAOYSA-M ac1l2skh Chemical compound [O-]Cl(=O)(=O)=O.C1CCN2CCCC3=C2C1=C1OC2=C(CCC4)C5=[N+]4CCCC5=CC2=C(C#N)C1=C3 HACOCUMLBPNDIN-UHFFFAOYSA-M 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102000004225 Cathepsin B Human genes 0.000 description 4
- 108090000712 Cathepsin B Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010405 reoxidation reaction Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 239000002253 acid Chemical group 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002170 ethers Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003568 thioethers Chemical group 0.000 description 2
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- GNTIRRQEPHPUCI-UHFFFAOYSA-N 2-[2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethylamino]-2-oxoethoxy]acetic acid Chemical compound NCCOCCOCCOCCNC(=O)COCC(O)=O GNTIRRQEPHPUCI-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- VIQOJEWMMVYGHA-UHFFFAOYSA-N CC(COCC(NCCOCCOCCOCCN)=O)=O Chemical compound CC(COCC(NCCOCCOCCOCCN)=O)=O VIQOJEWMMVYGHA-UHFFFAOYSA-N 0.000 description 1
- DLGHSVNJFLBAIF-UHFFFAOYSA-N CNc1ccc(C(C2C=CC(NC)=CC2O2)c3ccccc3C(O)O)c2c1 Chemical compound CNc1ccc(C(C2C=CC(NC)=CC2O2)c3ccccc3C(O)O)c2c1 DLGHSVNJFLBAIF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- JSEXODXREFNDRS-UHFFFAOYSA-N N#CC1c2cc(CCC3)c4N3CCCc4c2Oc2c1cc1c3c2CCCN3CCC1 Chemical compound N#CC1c2cc(CCC3)c4N3CCCc4c2Oc2c1cc1c3c2CCCN3CCC1 JSEXODXREFNDRS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- LMXKEVAPNOHFHY-UHFFFAOYSA-N NC(NCCCC(C(Nc1ccc(C(c2ccccc2C(O)=O)c(c(O2)c3)ccc3NC(C(CCCNC(N)=N)NC(c3ccccc3)=O)=O)c2c1)=O)NC(c1ccccc1)=O)=N Chemical compound NC(NCCCC(C(Nc1ccc(C(c2ccccc2C(O)=O)c(c(O2)c3)ccc3NC(C(CCCNC(N)=N)NC(c3ccccc3)=O)=O)c2c1)=O)NC(c1ccccc1)=O)=N LMXKEVAPNOHFHY-UHFFFAOYSA-N 0.000 description 1
- 0 Nc1ccc(C(c(ccc(O)c2)c2O2)*3c(CO)cccc3)c2c1 Chemical compound Nc1ccc(C(c(ccc(O)c2)c2O2)*3c(CO)cccc3)c2c1 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZLRVWFDVJWKAIL-LXMACRGBSA-M [2,2-dimethyl-3-[(2r,3e)-3-oxidoiminobutan-2-yl]azanidylpropyl]-[(2r,3e)-3-hydroxyiminobutan-2-yl]azanide;oxotechnetium-99(3+) Chemical compound [99Tc+3]=O.O/N=C(\C)[C@@H](C)[N-]CC(C)(C)C[N-][C@H](C)C(\C)=N\[O-] ZLRVWFDVJWKAIL-LXMACRGBSA-M 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 108010091858 peptide Q Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000747 poly(lactic acid) Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- NONOKGVFTBWRLD-UHFFFAOYSA-N thioisocyanate group Chemical group S(N=C=O)N=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
【選択図】 なし
Description
式中、
Qは還元型の蛍光色素を表し、
Rは親水基を表し、
Lはリンカーを表し、
pは、1〜4の整数を表す。
式中、Qは還元型の蛍光色素を表し、
Eは酵素が認識できるものを表し、
nは1〜3の整数を表し、
Rは親水基を表し、
Lはリンカーを表し、
rは0〜4の整数を表す。
i)活性化白血球によって生成するオキシダントとの反応によってインビボでの蛍光特性が変化する光学イメージング用造影剤を被検体に投与し、
ii)造影剤の蛍光特性の変化を検出すること
を含む方法である。
0.1Mホウ酸緩衝液(pH8.5)中の1mMローダミン800(Fluka社製、製造番号83701)溶液2mLに、約5mgの水素化ホウ素ナトリウムを添加した。混合物を振盪し、室温で2時間放置した。この還元型溶液40μLを960μLのリン酸緩衝食塩水(pH7.4)に添加した。図1Aは、Hewlett−Packard社製ダイオードアレイ分光光度計で記録した還元型ローダミン蛍光色素、すなわちジヒドロローダミン800のスペクトルである(点線)。未処理ローダミン800のスペクトルを全く同じ方法で記録した(実線)。希釈した還元型蛍光色素の試料を空気中で穏やかに酸化して、そのスペクトルを記録した(破線)。図1Bに、ローダミン800及びジヒドロローダミン800の化学式を示す。
0.1Mホウ酸緩衝液(pH8.5)中の1mMローダミン110(Fluka社製、製造番号83695)溶液2mLに、約5mgの水素化ホウ素ナトリウムを添加した。混合物を振盪し、室温で2時間放置した。この還元型溶液40μLを960μLのリン酸緩衝食塩水(pH7.4)に添加した。図2Aは、Hewlett−Packard社製ダイオードアレイ分光光度計で記録した還元型ローダミン蛍光色素、すなわちジヒドロローダミン110のスペクトルである(点線)。未処理ローダミン110のスペクトルを全く同じ方法で記録した(実線)。希釈した還元型蛍光色素の試料を空気中で穏やかに酸化して、そのスペクトルを記録した(破線)。図2Bに、ローダミン110及びジヒドロローダミン110の化学式を示す。
0.1Mホウ酸緩衝液(pH8.5)中の1mMフルオレセイン(Sigma社製、製造番号F−6377)溶液2mLに、約5mgの水素化ホウ素ナトリウムを添加した。混合物を振盪し、室温で2時間放置した。この還元型溶液40μLを960μLのリン酸緩衝食塩水(pH7.4)に添加した。図3Aは、Hewlett−Packard社製ダイオードアレイ分光光度計で記録した還元型フルオレセイン蛍光色素、すなわちジヒドロフルオレセインのスペクトルである(点線)。未処理フルオレセインのスペクトルを全く同じ方法で記録した(実線)。希釈した還元型蛍光色素の試料を空気中で穏やかに酸化して、そのスペクトルを記録した(破線)。図3Bに、フルオレセイン(蛍光性)及びジヒドロフルオレセイン(非蛍光性)の化学式を示す。
ローダミン110を実施例2と同様に還元した。還元型ローダミン110(すなわちジヒドロローダミン110)溶液の一部に、過酸化水素を最終濃度が10μMとなるまで添加し、蛍光の増加をThermo Fluoroscan Ascent FL蛍光光度計を用いて538nm(励起波長485nm)で記録した。実験は、図4Aに示すように、低濃度の過酸化水素で還元型ローダミン110が急速に酸化されることを示している。図4Bに、ジヒドロローダミン110及びローダミン110の化学式を示す。
Claims (17)
- 次の式(I)の光学イメージング用造影剤。
Q−(L−R)p (I)
式中、
Qは還元型の蛍光色素を表し、
Rは親水基を表し、
Lはリンカーを表し、
pは1〜4の整数を表す。 - Qが還元型のフルオレセイン又はローダミンから選択される、請求項1記載の光学イメージング用造影剤。
- Qがジヒドロフルオレセイン、ジクロロジヒドロフルオレセイン、ジヒドロローダミン123、ジヒドロローダミン6G、ジヒドロローダミン110、ジヒドロローダミン800、ジヒドロローダミンB、還元型スルホローダミンB及びジヒドロエチジウムからなる群から選択される、請求項1又は請求項2記載の光学イメージング用造影剤。
- Rがスルホン酸基、カルボキシレート基、カルボキシアルキル基、アルコキシカルボニル基、アルコキシアルキル基、アミノ基、糖類、線状又は環状ポリオール及び親水性ポリマーからなる群から選択される、請求項1乃至請求項3のいずれか1項記載の光学イメージング用造影剤。
- 活性化白血球によって生成するオキシダントとの反応によってインビボでの蛍光特性が変化する、請求項1乃至請求項4のいずれか1項記載の光学イメージング用造影剤。
- 蛍光特性の変化が、蛍光の出現又は消滅の変化、発光及び/又は励起波長の変化、蛍光強度レベルの変化又は蛍光寿命の変化である、請求項1乃至請求項5のいずれか1項記載の光学イメージング用造影剤。
- 造影剤とオキシダントとの反応が、1以上の二重結合の形成、ヒドロキシル基からケト基又はアルデヒド基への変換、或いはハロゲン原子又は窒素含有基による水素原子の置換を伴う、請求項5又は請求項6記載の光学イメージング用造影剤。
- 次の式(III)の酵素基質である光学イメージング用造影剤。
(R−L)r−Q−En (III)
式中、Qは還元型の蛍光色素を表し、
Eは酵素が認識できるものを表し、
nは1〜3の整数を表し、
Rは親水基を表し、
Lはリンカーを表し、
rは0〜4の整数である。 - 酵素反応に加えてオキシダントとの反応による蛍光特性の変化を含むインビボでの二段階機構で活性化される、請求項8記載の光学イメージング用造影剤。
- ペプチダーゼ、プロテアーゼ、ホスファターゼ、スルファターゼ、グルコシダーゼ、エステラーゼ、デヒドロゲナーゼ、オキシダーゼ、レダクターゼ、キナーゼ、トランスフェラーゼ及びリガーゼからなる群から選択される酵素に対する酵素基質である、請求項8又は請求項9記載の光学イメージング用造影剤。
- 還元型のフルオレセイン類及びローダミン類からなる群から選択される蛍光色素Qを含む、請求項8乃至請求項10のいずれか1項記載の造影剤。
- ジヒドロフルオレセイン、ジクロロジヒドロフルオレセイン、ジヒドロローダミン123、ジヒドロローダミン6G、ジヒドロローダミン110、ジヒドロローダミン800、ジヒドロローダミンB、還元型スルホローダミンB及びジヒドロエチジウムからなる群から選択される蛍光色素Qを含む、請求項8乃至請求項11のいずれか1項記載の造影剤。
- インビボ光学イメージングによって組織中の活性化白血球を検出する方法であって、
i)活性化白血球によって生成するオキシダントとの反応によってインビボでの蛍光特性が変化する光学イメージング用造影剤を被検体に投与し、
ii)造影剤の蛍光特性の変化を検出すること
を含む方法。 - 造影剤が加水分解酵素の基質であり、造影剤がオキシダントとの反応前に酵素反応を受ける、請求項13記載の方法。
- 請求項1乃至請求項12のいずれか1項記載の造影剤を、薬学的に許容される1種以上の補助剤、賦形剤又は希釈剤と共に含んでなる組成物。
- 炎症の診断に用いられるコントラスト強調剤の製造における、請求項1乃至請求項12のいずれか1項記載の造影剤の使用。
- 炎症部位の検出のための診断イメージングに使用するための請求項1乃至請求項11のいずれか1項記載の造影剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20045435 | 2004-12-13 | ||
NO20045435 | 2004-12-13 | ||
PCT/NO2005/000458 WO2006065146A2 (en) | 2004-12-13 | 2005-12-13 | Fluorescent contrast agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008523056A true JP2008523056A (ja) | 2008-07-03 |
JP2008523056A5 JP2008523056A5 (ja) | 2009-02-05 |
JP5015794B2 JP5015794B2 (ja) | 2012-08-29 |
Family
ID=35945184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007545401A Expired - Fee Related JP5015794B2 (ja) | 2004-12-13 | 2005-12-13 | 蛍光造影剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20090238765A1 (ja) |
EP (2) | EP2025349A3 (ja) |
JP (1) | JP5015794B2 (ja) |
CN (1) | CN101115507A (ja) |
WO (1) | WO2006065146A2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906106B2 (en) | 2007-06-27 | 2011-03-15 | General Electric Company | In vivo cell trafficking |
WO2009139972A2 (en) * | 2008-03-31 | 2009-11-19 | University Of Louisville Research Foundation, Inc. | Site specific fluorescence marking and contrast marker for same |
CN103214875B (zh) * | 2013-03-04 | 2014-08-27 | 大连理工大学 | 一类以荧光素类似物为母体的荧光染料的合成和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0263877A1 (en) * | 1986-04-11 | 1988-04-20 | The President And Fellows Of Harvard College | Dihydrorhodamines and halogenated derivatives thereof |
US5905031A (en) * | 1995-05-18 | 1999-05-18 | Coulter International Corp. | Identification of blast cells in a leukocyte cell preparation |
US5773236A (en) * | 1997-04-25 | 1998-06-30 | Molecule Probes, Inc. | Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules |
AU8224998A (en) * | 1997-07-04 | 1999-01-25 | Nycomed Amersham Plc | Peroxidase-catalysed fluorescence |
US6265179B1 (en) * | 2000-02-01 | 2001-07-24 | Molecular Probes, Inc. | Detection of phosphate using coupled enzymatic reactions |
WO2001066789A1 (en) | 2000-03-09 | 2001-09-13 | U.S. Army Institute Of Surgical Research | Rapid screening procedure for inflammation mediators |
-
2005
- 2005-12-13 CN CNA2005800480417A patent/CN101115507A/zh active Pending
- 2005-12-13 EP EP08015992A patent/EP2025349A3/en not_active Withdrawn
- 2005-12-13 EP EP05817664A patent/EP1824522A2/en not_active Withdrawn
- 2005-12-13 US US11/721,346 patent/US20090238765A1/en not_active Abandoned
- 2005-12-13 JP JP2007545401A patent/JP5015794B2/ja not_active Expired - Fee Related
- 2005-12-13 WO PCT/NO2005/000458 patent/WO2006065146A2/en active Application Filing
-
2011
- 2011-07-15 US US13/183,687 patent/US20110318273A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110318273A1 (en) | 2011-12-29 |
US20090238765A1 (en) | 2009-09-24 |
EP2025349A3 (en) | 2013-03-13 |
WO2006065146A2 (en) | 2006-06-22 |
EP1824522A2 (en) | 2007-08-29 |
EP2025349A2 (en) | 2009-02-18 |
JP5015794B2 (ja) | 2012-08-29 |
WO2006065146A3 (en) | 2006-08-31 |
CN101115507A (zh) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8841320B2 (en) | Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging | |
JP6606487B2 (ja) | invitroおよびinvivoイメージングおよび検出のための置換シラキサンテニウム赤色〜近赤外蛍光色素 | |
EP3510399B1 (en) | Psma-targeted nir dyes and their uses | |
US9180209B2 (en) | Non-peptidic quenched fluorescent imaging probes | |
JP5523282B2 (ja) | 蛍光コバラミンおよびその使用 | |
CN110023740B (zh) | 基于活性的探针化合物、组合物及其使用方法 | |
WO2007008080A2 (en) | Optical imaging contrast agents | |
EP1370291B1 (en) | Device and method for the photodynamic diagnosis of tumor tissue | |
US6905884B2 (en) | Fluorescent cobalamins and uses thereof | |
JP5015794B2 (ja) | 蛍光造影剤 | |
JP5350570B2 (ja) | 蛍光性コバラミンおよびその使用 | |
JP2018511556A (ja) | in vivo画像化のためのプロテアーゼ活性化コントラスト剤 | |
JP7149614B2 (ja) | in vivo画像化のためのプロテアーゼ活性化コントラスト剤 | |
Zhang et al. | Labelling Matrix Metalloproteinases | |
Udukala | Protease assays for cancer diagnostics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081204 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081204 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110117 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110906 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111206 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120508 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120607 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150615 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |